Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone acetonide parotid lavage for salivary secretion in Sjogren syndrome
ChiCTR2100052314Phase 4Not yet recruiting
- Sponsor
- Affiliated Stomatological Hospital of Nanjing Medical University
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triamcinolone acetonide in Sjögren's syndrome (2 arms), sponsored by Affiliated Stomatological Hospital of Nanjing Medical University. Primary endpoints: Acid-stimulated parotid salivary flow rate and Resting parotid salivary flow rate. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2100052314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052314.